Dynamic Interleukin-1 Receptor Type 1 Signaling Mediates Microglia-Vasculature Interactions Following Repeated Systemic LPS.
BBB
neuroinflammation
perivascular microglia
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
11
2021
accepted:
16
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Lipopolysaccharide (LPS) preconditioning involves repeated, systemic, and sub-threshold doses of LPS, which induces a neuroprotective state within the CNS, thus preventing neuronal death and functional losses. Recently, proinflammatory cytokine, Interleukin-1 (IL-1), and its primary signaling partner, interleukin-1 receptor type 1 (IL-1R1), have been associated with neuroprotection in the CNS. However, it is still unknown how IL-1/IL-1R1 signaling impacts the processes associated with neuroprotection. Using our IL-1R1 restore genetic mouse model, mouse lines were generated to restrict IL-1R1 expression either to endothelia ( Following 4d LPS, we found multiple phenotypes that are dependent on IL-1R1 signaling such as microglia morphology alterations, increased microglial M2-like gene expression, and clustering of microglia onto the brain vasculature. We determined that 4d LPS induces microglial morphological changes, clustering at the vasculature, and gene expression changes are dependent on endothelial IL-1R1, but not microglial IL-1R1. A novel observation was the induction of microglial IL-1R1 (mIL-1R1) following 4d LPS. The induced mIL-1R1 permits a unique response to central IL-1β: the mIL-1R1 dependent induction of IL-1R1 antagonist (IL-1RA) and IL-1β gene expression. Analysis of RNA sequencing datasets revealed that mIL-1R1 is also induced in neurodegenerative diseases. Here, we have identified cell type-specific IL-1R1 mediated mechanisms, which may contribute to the neuroprotection observed in LPS preconditioning. These findings identify key cellular and molecular contributors in LPS-induced neuroprotection.
Identifiants
pubmed: 35282272
doi: 10.2147/JIR.S350114
pii: 350114
pmc: PMC8906862
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1575-1590Subventions
Organisme : NIMH NIH HHS
ID : R01 MH109165
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS116914
Pays : United States
Organisme : NIDCR NIH HHS
ID : T32 DE014320
Pays : United States
Informations de copyright
© 2022 Nemeth et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Neurosci. 2020 Nov 18;40(47):9103-9120
pubmed: 33051350
Front Pharmacol. 2018 May 01;9:416
pubmed: 29765321
Nat Commun. 2020 Jul 23;11(1):3687
pubmed: 32703941
J Immunol. 1989 Dec 1;143(11):3556-61
pubmed: 2511244
Brain Behav Immun. 2019 Oct;81:292-304
pubmed: 31228609
Cell Rep. 2018 Jan 16;22(3):832-847
pubmed: 29346778
J Neurosci. 2005 Feb 16;25(7):1788-96
pubmed: 15716415
Brain Behav Immun. 2017 Nov;66:165-176
pubmed: 28655587
J Neurosci. 2016 Mar 02;36(9):2590-604
pubmed: 26937001
Cell. 2007 Sep 7;130(5):918-31
pubmed: 17803913
J Neuroinflammation. 2015 Nov 25;12:223
pubmed: 26608623
Brain Behav Immun. 2010 Jan;24(1):102-9
pubmed: 19735725
Biol Psychiatry. 2016 May 15;79(10):803-813
pubmed: 26281717
Mol Psychiatry. 2021 Sep;26(9):4770-4782
pubmed: 32444870
J Neurosci. 2009 Oct 28;29(43):13435-44
pubmed: 19864556
Brain Behav Immun. 2015 Aug;48:205-21
pubmed: 25843371
J Neurochem. 2002 Nov;83(4):754-63
pubmed: 12421347
Glia. 2016 Feb;64(2):300-16
pubmed: 26470014
Cell Mol Neurobiol. 2016 Nov;36(8):1269-1277
pubmed: 27048218
Int J Mol Sci. 2017 Aug 23;18(9):
pubmed: 28832497
J Neurosci. 2015 Feb 18;35(7):2860-70
pubmed: 25698726
Brain Pathol. 1998 Oct;8(4):625-40
pubmed: 9804372
Brain Behav Immun. 2012 Jul;26(5):766-77
pubmed: 22024136
J Neuroinflammation. 2012 Apr 07;9:65
pubmed: 22483094
Neuroscience. 1998 Mar;83(1):281-93
pubmed: 9466417
Stroke. 2010 Jul;41(7):1543-51
pubmed: 20508195
Acta Neurochir Suppl. 2013;115:253-8
pubmed: 22890677
Stroke. 2004 Nov;35(11):2576-81
pubmed: 15375302
Immunity. 2019 Feb 19;50(2):317-333.e6
pubmed: 30683620
J Neuroinflammation. 2011 Oct 14;8:140
pubmed: 21999375
Mol Psychiatry. 2019 Oct;24(10):1533-1548
pubmed: 29875474
J Neurosci. 2012 Aug 22;32(34):11706-15
pubmed: 22915113
FASEB J. 2005 Nov;19(13):1914-6
pubmed: 16172186
Trends Immunol. 2019 Apr;40(4):358-374
pubmed: 30833177
Cell Rep. 2020 Jun 30;31(13):107843
pubmed: 32610143
Nat Commun. 2019 Dec 20;10(1):5816
pubmed: 31862977
J Neuroinflammation. 2017 Jul 1;14(1):133
pubmed: 28668091
Antimicrob Agents Chemother. 2013 Sep;57(9):4336-4342
pubmed: 23796941
J Neurosci Res. 2014 Dec;92(12):1647-58
pubmed: 25044014